Clinical trials: Non Hodgkin Lymphoma
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01307267
- Testing
- PF-05082566, rituximab
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 190 people
- Sponsor
- Pfizer
Diffuse Large B-cell Lymphoma
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
To evaluate the real-world efficacy of Tafasitamab combined with Lenalidomide base regimen in patients with relapsed or refractory DLBCL, with objective response rate as the primary end point.
- Trial name
- NCT05883709
- Testing
- Tafasitamab Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhao Weili
Primary Hypertension, Grade 2
Aerobic Exercise vs Physiological Ischemic Training in Stage 2 Hypertension
This study aims to compare the effects of aerobic exercise (AE) and physiological ischemic training (PIT) on inflammatory and angiogenesis biomarkers (VEGF, IL-6, IL-10), cardiorespiratory fitness, muscle strength, and quality of…
- Trial name
- NCT07375407
- Testing
- Aerobic Exercise (AE), Physiological Ischemic Training (PIT)
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- Universitas Padjadjaran
Moderate or Severe Submental Fullness
Patient Experience Study of Deoxycholic Acid Injection
The objectives of this study are to determine the safety of deoxycholic acid subcutaneous (SC) injections in the submental area and to evaluate the effects of four interventions, relative to placebo in the submental area…
- Trial name
- NCT02007434
- Testing
- Deoxycholic Acid Injection, Cold Compress, Lidocaine / Epinephrine
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Kythera Biopharmaceuticals
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has…
- Trial name
- NCT07003295
- Testing
- Biospecimen Collection, Computed Tomography, Glofitamab
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma.
- Trial name
- NCT00669877
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
B-Cell Non-Hodgkin Lymphoma (NHL)
Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Establishing real-world data of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) treated with Ranicabtagene Autoleucel Injection to evaluate its efficacy and safety.
- Trial name
- NCT07888530
- Testing
- Ranicabtagene Autoleucel Injection
- Volunteers
- 200 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Ublituximab + Ibrutinib in Select B-cell Malignancies
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
- Trial name
- NCT02013128
- Testing
- Ublituximab, Ibrutinib
- Where
- 18 sites in United States
- Volunteers
- 66 people
- Sponsor
- TG Therapeutics, Inc.
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A).
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Trial name
- NCT01421667
- Testing
- brentuximab vedotin, rituximab
- Where
- 34 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Seagen Inc.
Malnutrition; Moderate
The Correlation Among Nutrition, Muscle Strength, Masticatory and Swallow Ability of Inpatient Elders
The masticatory performance would affect the nutritional status of elderly people. the prevalence of undernutrition among elderly inpatients is %20-50%.
- Trial name
- NMM (NCT04492644)
- Testing
- No intervention
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- China Medical University Hospital
Peripheral T-cell Lymphoma
A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
The study is being conducted to evaluate the safety and efficacy of SHR2554 with CHOP/CHOEP in treatment- naïve peripheral T-cell lymphoma.
- Trial name
- NCT06173999
- Testing
- SHR2554/CHOP, SHR2554/CHOEP
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
This phase I trial studies the side effects and best dose of alisertib and romidepsin in treating patients with B-cell or T-cell lymphomas that have returned after a period of improvement (relapsed) or have not responded to…
- Conditions
- MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT01897012
- Testing
- Alisertib, Laboratory Biomarker Analysis, Romidepsin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkins Lymphoma
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.
- Trial name
- NCT00054834
- Testing
- hLL2 (epratuzumab)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Gilead Sciences
Grade I and II Knee Meniscal Injuries
For Grade I and II Knee Meniscal Injuries Patients ,Glucosamine, Chondroitin and Some Herbs Extract Phonophoresis Will Be Used (A) Versus Placebo(B)
Hypothesis: In grade I and II meniscal injury patients, 1) GL and CH (PH) decrease knee pain severity measured by Numerical Rating Scales (NRS) more than only topical application.
- Trial name
- NCT06798428
- Testing
- group A will receive ultrasound phonophoresis (Glucosamine, Chondroitin and Some Herbs Extract ), Group B will receive ultrasound with topical gel , same parameter as group A
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Eslam Elsayed Ali Shohda
Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical…
- Trial name
- NCT03117036
- Testing
- Chemotherapy
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
Lymphoma, Follicular, Lymphoma, Mantle-Cell
A Phase 1 Study of ADI-001 in B Cell Malignancies
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- GLEAN-1 (NCT04735471)
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Adicet Therapeutics
Non-Hodgkin's Lymphoma
High Dose CHOP in Lymphoma
The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome.
- Trial name
- NCT00192764
- Testing
- high-dose cyclophosphamide
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Rambam Health Care Campus
Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00703664
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
RATIONALE: Inserting the gene for RevM10 into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
- Trial name
- NCT00003942
- Testing
- RevM10 gene, RevM10/polAS gene, in vitro-treated peripheral blood stem cell transplantation
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Systemix
Lymphoma, Non Hodgkin
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
This open-label, single-arm, phase IIIb study will evaluate the safety of switching from intravenous (IV) to subcutaneous (SC) administration of rituximab during first-line treatment for participants with CD20+ non-Hodgkin's…
- Trial name
- NCT01987505
- Testing
- Rituximab
- Where
- 39 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.